Page last updated: 2024-12-10
furcellaran
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
furcellaran: alginate rich in iodine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 4054780 |
SCHEMBL ID | 620331 |
MeSH ID | M0060401 |
Synonyms (20)
Synonym |
---|
furcellaran |
STK689789 |
AKOS005601843 |
2-chloro-7-nitroquinoxaline , |
9000-21-9 |
2-chloro-7-nitro-quinoxaline |
DCWHGXURAAYUEC-UHFFFAOYSA-N |
55686-94-7 |
FT-0684433 |
GF-0726 |
AM20120678 |
quinoxaline, 2-chloro-7-nitro- |
SCHEMBL620331 |
DTXSID20398815 |
mfcd00033669 |
J-508995 |
CS-0019225 |
A870132 |
EN300-7373058 |
Z1269201545 |
Research Excerpts
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
" Hence, the present study focused on improving the bioavailability of the antioxidant peptides from CSGH and on the use of furcellaran (FUR), which can protect the biopeptides during digestion in the gastrointestinal tract." | ( Furcellaran-Coated Microcapsules as Carriers of Borczak, B; Jamróz, E; Kapusta-Duch, J; Morawska, M; Piątkowska, E; Tkaczewska, J, 2019) | 2.16 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (22)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (4.55) | 18.7374 |
1990's | 2 (9.09) | 18.2507 |
2000's | 1 (4.55) | 29.6817 |
2010's | 5 (22.73) | 24.3611 |
2020's | 13 (59.09) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 34.90
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (34.90) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (4.17%) | 6.00% |
Case Studies | 1 (4.17%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 22 (91.67%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |